SCHEMBL1638736

SCHEMBL1638736

[c]1cc(-c2ccc3c(c2)OCO3)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 3/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 3/20 0.47
RAB9A P51151 3/20 0.47
LMNA P02545 3/20 0.47
POLB P06746 2/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
HSD17B10 Q99714 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SNCA P37840 1/20 0.46
DCUN1D1 Q96GG9 2/20 0.46
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
NISCH Q9Y2I1 1/20 0.45
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31672261 0.73 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL31703271 0.73 DCUN1D1 (0.51) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL10057827 0.72 SNCA (0.77) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL6250827 0.71 SNCA (0.56) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL9739930 0.70 NPC1 (0.54) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL21373510 0.70 ALDH1A1 (0.52) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL5612730 0.69 KDM4E (0.48) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL13516895 0.69 KDM4E (0.51) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL30176724 0.69 DCUN1D1 (0.56) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL16539308 0.69 SNCA (0.53) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 KDM4E 4638/4885SMN1; SMN2 486/4885ALDH1A1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.